Lusduna (insulin glargine biosimilar) / Samsung - LARVOL DELTA

Direct Tumor Killing and Immunotherapy through Anti-SerpinB9 Therapy. (PubMed, Cell) - "The therapeutic utility of Sb9 inhibition was demonstrated by the control of tumor growth, resulting in increased survival times in mice. Our studies describe a molecular target that permits a combination of tumor ablation, interference within the TME, and immunotherapy in one potential modality."

Journal • Oncology • GZMB

Design, synthesis, modelling studies and biological evaluation of 1,3,4-oxadiazole derivatives as potent anticancer agents targeting thymidine phosphorylase enzyme. (PubMed, Bioorg Chem) - "The TP assay identified SB8 and SB9 as potential inhibitors with anti-cancer activity against both the cell lines. The SARs study of synthesized derivatives revealed that the substitution of phenyl ring with electron withdrawing group at ortho position showed significant TP inhibitory activity compared to para substitution. The experimental data suggests that 1,3,4-oxadiazole with substituted phenyl can be taken as a lead for the design of efficient TP inhibitors and active compounds which can be taken up for further studies."

Journal • Breast Cancer • Oncology • Solid Tumor

Effects of Bacillus subtilis and its metabolites on corn silage quality. (PubMed, Lett Appl Microbiol) - "We comparedthe results among silage without inoculant (SC) and silages inoculated with B. subtilis 8 log CFU Kg forage (SB8), 9 log CFU Kg forage (SB9), and 9.84 log CFU Kg forage + β-glucosidase enzyme (SBE). Yeast populations were low for all silages, irrespective of the different treatments, and the presence of filamentous fungi was observed only in the SBE-treated silage. Among all silage treatments, SB9 treatment resulted in the highest aerobic stability."

Journal

Bupivacaine local anesthetic to decrease opioid requirements after radical cystectomy: Does formulation matter? (PubMed, Urol Oncol) - "Among patients undergoing RC under ERAS protocol there was no significant difference in postoperative opioid consumption, NRS pain scores, or length of stay among patients receiving SB compared to LB."

Journal • Anesthesia • Bladder Cancer • Genito-urinary Cancer • Lip Cancer • Oncology • Pain • Solid Tumor • Urothelial Cancer

Biosimilars and Novel Insulins. (PubMed, Am J Ther) - "Biosimilar insulins have comparable PK-PD profiles and equivalent efficacy and safety to original insulins at a lower price, making them available for more people with diabetes. Faster aspart is the first ultrafast-acting insulin. New upcoming clinical trials and more clinical experience with faster aspart will show the real potential of this new insulin."

Journal • Diabetes • Hypoglycemia • Metabolic Disorders • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients (clinicaltrials.gov) - P2; N=20; Enrolling by invitation; Sponsor: Profil Institut für Stoffwechselforschung GmbH; Recruiting ➔ Enrolling by invitation

Enrollment status • Biosimilar • Diabetes

Comparative evaluation of the new GRPR-antagonist In-SB9 and In-AMBA in prostate cancer models - Implications of in vivo stability. (PubMed, J Labelled Comp Radiopharm) - "In short, this study has revealed superior pharmacokinetics and higher stability for the GRPR-antagonist In-SB9 vs. the corresponding agonist In-AMBA consolidating previous evidence that GRPR-antagonists are preferable to agonists for tumor imaging and therapy. It has also demonstrated that further pharmacokinetic improvements were feasible by in-situ metabolic radioligand stabilization using PA."

Journal • Preclinical

Formulary Considerations for Insulins Approved Through the 505(b)(2) "Follow-on" Pathway. (PubMed, Ann Pharmacother) - "Follow-on insulin products approved through the 505(b)(2) pathway are supported by robust efficacy and safety data. As new follow-on insulins are approved and the regulatory change that will occur with these products in 2020 approaches, formulary decisions and clinical policies (eg, substitution) will continue to be revisited."

Journal

Description of Halegenticoccus soli gen. nov., sp. nov., a halophilic archaeon isolated from a soil sample of Ebi lake. (PubMed, Extremophiles) - "The 16S rRNA gene sequence result revealed that the two strains were closely related to Haloprofundus marisrubri SB9 (92.7% similarity)...nov., is proposed. The type strain is SYAUA9-0 (= KCTC4241 = CGMCC 1.15765)."

Journal

BURDEN OF RESPIRATORY SYMPTOMS IN STABLE COPD PATIENTS FROM CENTRAL EASTERN EUROPE: RESULTS FROM A LARGE OBSERVATIONAL STUDY (CHEST 2019) - P=N/A; "Mean severity scores for DT symptoms were: BG 14.7, PL 13.2, RO 12.5, SK 11.4 and SB 9.8 – out of a maximum of 40, with higher scores representing more severe symptoms...Despite regular treatment, symptoms place a high burden in stable COPD patients from CEE countries. Symptoms are variable and impact daily life of patients.Clinical Implications:Comprehensive assessment of respiratory symptoms can prove beneficial towards a more personalized treatment of patients with COPD."

Clinical • Observational data

Haloprofundus halophilus sp. nov., isolated from the saline soil of Tarim Basin. (PubMed, Antonie Van Leeuwenhoek) - "...marisrubri SB9 were 85.22% and 29.3%, respectively...nov. is proposed."

Journal